FCF Biotech Venture Capital Monitor – USA 03/2021 published

FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Biotech Venture Capital Monitor – USA 03/2021”.

The Monitor is a monthly published overview of venture capital trends in the US-Biotech sector.

As of the end of March 2021, we identify the following current VC trends in the US-Biotech sector:

  • In 2021, overall Biotech funding in the USA has reached USD 8,953m so far
  • Top 5 deals exceed USD 200m each, largest transaction amounted to USD 525m in EQRx, Inc.
  • Logos Capital (USA) still leads the Top 5 Investors (by deal volume), Cormorant Asset Management (USA) took over second rank followed by HBM Partners (Switzerland)
  • Oncology still dominates as the top indication

To access the full report, please click here.

By Dr. Mathias Schott, Sebastian Sommer and Alexander Kuhn

Share on linkedin
Share
Scroll Up